Biotechnology Innovation Organization

Humanetics Corporation to Present at the BIO International Convention in San Diego

Retrieved on: 
金曜日, 5月 31, 2024
Health, Radiology, Pharmaceutical, Clinical Trials, Oncology, Private law, Patient, Cancer, Biotechnology Innovation Organization, BIO

Humanetics Corporation, a clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA next week.

Key Points: 
  • Humanetics Corporation, a clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA next week.
  • This convention, known for its global reach and influence, provides a platform for industry leaders to showcase their innovations.
  • Ronald J. Zenk, Chief Executive Officer, will present this information on Monday, June 3, 2024 (1:30 pm Company Presentation Theatre 3).

Shaperon & Hudson to Participate in the 2024 Bio International Convention

Retrieved on: 
木曜日, 5月 30, 2024
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Clinical Trials, MASH, Veterinary medicine, Technology transfer, Obesity, AACR, Therapy, Animal, Atopic dermatitis, BIO, Ulcerative colitis, Biotechnology Innovation Organization

Hudson Therapeutics announced that Shaperon, Inc. (Kosdaq: 378800) and Hudson Therapeutics, Inc. which is the US Subsidiary of Shaperon will attend the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California to explore partnering opportunities.

Key Points: 
  • Hudson Therapeutics announced that Shaperon, Inc. (Kosdaq: 378800) and Hudson Therapeutics, Inc. which is the US Subsidiary of Shaperon will attend the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California to explore partnering opportunities.
  • The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering, attracting global biotechnology and biopharmaceutical leaders.
  • The event offers networking, programming, and partnering and investor opportunities.
  • BIO’s One-on-One Partnering™ facilitates meetings with senior biotech executives, business development leaders, and investors, with over 57,000 partnering meetings held at the last in-person BIO convention.

Pattern to Present at 2024 BIO International Convention

Retrieved on: 
火曜日, 5月 21, 2024
Pattern, PDE, AI, Research, Cancer, BIO, Biotechnology Innovation Organization

REDMOND, Wash., May 21, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will present at the upcoming 2024 BIO International Convention, June 3 - 6, 2024, in San Diego, California.

Key Points: 
  • REDMOND, Wash., May 21, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will present at the upcoming 2024 BIO International Convention, June 3 - 6, 2024, in San Diego, California.
  • Mr. Anderson will present to senior biotech executives, business development leaders and investors Wednesday, June 5 at 3:45 PM in Comany Presentation Theater 3.
  • The BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the largest global event for the biotech industry, gathering more than 15,000 leaders in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.
  • Pattern is optimally positioned to leverage the expertise of our Pattern Discovery Engine™ (PDE) into the next worlds of trustworthy, transparent computing.

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

Retrieved on: 
水曜日, 5月 15, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Axys, Novartis, Celera Corporation, GSK, Ironwood Pharmaceuticals, OncoMed, GSK plc, Regenerative medicine, Genzyme, International business, BIO, University, Patient, Business administration, General partnership, Chairperson, Therapy, Vertex Pharmaceuticals, DDX, NAMS, Acquisition, QLT, BCG, BLA, Pharmacy, Worldwide, Biotechnology Innovation Organization, Management

enGene’s Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson.

Key Points: 
  • enGene’s Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson.
  • “We are pleased to welcome Paul and Wouter to our Board of Directors.
  • “The Company is well-positioned for success, and I look forward to working with the management team to execute its vision.”
    Mr. Joustra said, “I’m thrilled to join enGene’s Board of Directors.
  • Currently Mr. Joustra serves on the board of directors of VectorY Therapeutics and holds a position as a board observer at NewAmsterdam Pharma N.V. (NASDAQ: NAMS).

Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention

Retrieved on: 
土曜日, 5月 11, 2024
Cellulite, Connective tissue, Biotechnology, Dercum's disease, San Diego Convention Center, Biotechnology Innovation Organization, PDT, BIO

NEW TAIPEI CITY, May 11, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT.

Key Points: 
  • NEW TAIPEI CITY, May 11, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT.
  • The presentation will take place in Company Presentation Theater 2 at the San Diego Convention Center.
  • The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), stands as the world's premier industry event, convening over 20,000 esteemed biotechnology and pharmaceutical leaders from around 5,000 reputable companies.
  • Caliway anticipates this opportunity to share recent progress on its lead pipeline candidate, CBL-514, with the international biotechnology and pharmaceutical community.

Global Health Leaders Unite to Confront Urgent Public Health Crisis of Antimicrobial Resistance

Retrieved on: 
火曜日, 5月 7, 2024
Public Policy, Government, Other Communications, General Health, Health, Other Policy Issues, Infectious Diseases, Communications, Public, Cancer, Antimicrobial resistance, Social isolation, Pathogenic bacteria, Risk, Malaria, CDC, Animal, AMR, Death, Biotechnology Innovation Organization, Parent, Research, BIO, Plant, Friends, Environment, Human, Partnership, Disease, Family, JD, Patient, Caregiver, Face, Diary, Child, HIV, Infection, Associate, TB, COVID-19, Diplomatic rank, Pharmaceutical industry

Awareness that is desperately needed because significant worldwide efforts to date have yet to penetrate global consciousness about this public health emergency.

Key Points: 
  • Awareness that is desperately needed because significant worldwide efforts to date have yet to penetrate global consciousness about this public health emergency.
  • "Antimicrobial resistance is an urgent global public health threat that poses risks to modern medicine, the health of humans, animals, plants, the environment, and the global economy.
  • These stories are poised to transform the AMR crisis from a distant concept to a relatable and urgent reality.
  • Putting a human face on this global emergency is critical to motivating action that can change the course of this escalating health crisis.

Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C.

Retrieved on: 
火曜日, 5月 7, 2024
Public, Summit, Partner, Risk, Policy, Disability, Advocacy, Kyowa Kirin, Spark Therapeutics, Biotechnology Innovation Organization, Human, BIO, Communication, Public policy, Novartis, Patient, MPH, Patient advocacy, Conditional sentence, Madison Hotel, Visual impairment, CVC, Knowledge, Mallinckrodt, Nursing

CHICAGO, May 7, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, will be hosting the ASPECT Patient Engagement and Advocacy Summit, May 14-16, 2024, at the Madison Hotel in Washington, D.C. The Summit will bring together ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program graduates (eye health patients and their allies), and program sponsors.

Key Points: 
  • Three-day event brings together patients, care partners, and public health champions to advance the goals of the Prevent Blindness ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program
    CHICAGO, May 7, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, will be hosting the ASPECT Patient Engagement and Advocacy Summit, May 14-16, 2024, at the Madison Hotel in Washington, D.C.
  • The Summit will bring together ASPECT (Advocacy, Support, Perspective, Empowerment, Communication, and Training) Patient Engagement Program graduates (eye health patients and their allies), and program sponsors.
  • The ASPECT Patient Engagement and Advocacy Summit is generously supported by Sustaining Level Partners Amgen, Genentech, and Novartis.
  • For information on Prevent Blindness advocacy efforts, please visit Advocacy.PreventBlindness.org , or contact Sara Brown, Director of Government Affairs, at [email protected] .

Admiral William McRaven to Keynote 2024 BIO Convention

Retrieved on: 
火曜日, 4月 30, 2024
Storm, Well, Education, University, Person of the Year, Policy, TIME, CFR, Medicine, Face, Bullfrog, University of Texas System, Nautical fiction, Special Operations Command, Council, Woman, Ambassador, SPEC, BIO, Navy, Admiral, Faculty, Democracy, Sea, Chancellor (education), National Football Foundation, Book, Foreign Policy, Biotechnology Innovation Organization, Research, Therapy, Foreign policy, Student, Organization, UT System, ConocoPhillips, Hero, Wisdom, Osama bin Laden, Convention, CIA

WASHINGTON, April 30, 2024 /PRNewswire/ -- As recent global events have demonstrated, the world has become more challenging and American leadership is needed more at home and abroad than ever before, and that includes maintaining U.S. dominance in biotechnology innovation. Retired U.S. Navy four-star admiral, Navy SEAL, University Chancellor, best-selling author and world-renowned authority of leadership, William McRaven, will keynote the 2024 BIO International Convention, Wednesday, June 5, in San Diego. Admiral McRaven will be interviewed by John Crowley, CEO of the Biotechnology Innovation Organization (BIO) about the challenge of global events today and the implications for biotechnology as a national security imperative. McRaven will also share his insights on essential elements of leadership in managing complex organizations.

Key Points: 
  • Retired U.S. Navy four-star admiral, Navy SEAL, University Chancellor, best-selling author and world-renowned authority of leadership, William McRaven, will keynote the 2024 BIO International Convention, Wednesday, June 5, in San Diego.
  • Admiral McRaven will be interviewed by John Crowley, CEO of the Biotechnology Innovation Organization (BIO) about the challenge of global events today and the implications for biotechnology as a national security imperative.
  • The Convention will take place at the San Diego Convention Center from June 3 – 6, 2024.
  • Admiral William H. McRaven is a retired U.S. Navy Four-Star admiral and the former Chancellor of the University of Texas System.

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

Retrieved on: 
水曜日, 4月 17, 2024
MASH, Executive, Marketing, Eli Lilly, Genentech, Biotechnology Innovation Organization, Piz Sardona, Liver, Patient, Acquisition, Circulatory system, Northwestern University, Eli Lilly and Company, Trade, Therapy, SAN, Pharmaceutical industry

Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics.

Key Points: 
  • Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics.
  • “As 89bio executes on its ongoing Phase 3 programs for pegozafermin, this is an opportune time to add an industry leader like Martin to our board,” said Rohan Palekar, Chief Executive Officer of 89bio.
  • Mr. Babler previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development.
  • I am excited to work alongside the management team and Board of Directors to bring pegozafermin to the many patients in need.”

Turnstone Biologics Appoints William Waddill to its Board of Directors

Retrieved on: 
火曜日, 4月 16, 2024
University, CFO, LLP, Champaign–Urbana metropolitan area, Certification, Arrowhead Pharmaceuticals, TILS, PwC, Biotechnology Innovation Organization, BIO, Selection, TIL, SVP, Senior, Patient, OncoMed, Therapy, Biotechnology, SAN, Pharmaceutical industry

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.

Key Points: 
  • SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.
  • The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors.
  • “I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone,” said Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer.
  • “Will is a highly accomplished biotechnology executive and Board member, and his impressive track record and deep operational and financial acumen make him a valuable addition to our Board.